FDA has accepted a supplemental New Drug Application for Rubraca (rucaparib) and granted priority review status to the application with a Prescription Drug User Fee Act date of May 15.
In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer.
